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Abstract
Background: Lymphoid Enhancer Factor-1 (Lef-1) is a member of a transcription factor family that acts as
downstream mediator of the Wnt/b-catenin signalling pathway which plays a critical role in osteoblast proliferation
and differentiation. In a search for Lef-1 responsive genes in human osteoblasts, we focused on the transcriptional
regulation of the SLUG, a zinc finger transcription factor belonging to the Snail family of developmental proteins.
Although the role of SLUG in epithelial-mesenchymal transition and cell motility during embryogenesis is well
documented, the functions of this factor in most normal adult human tissues are largely unknown. In this study we
investigated SLUG expression in normal human osteoblasts and their mesenchymal precursors, and its possible
correlation with Lef-1 and Wnt/b-catenin signalling.
Results: The experiments were performed on normal human primary osteoblasts obtained from bone fragments,
cultured in osteogenic conditions in presence of Lef-1 expression vector or GSK-3b inhibitor, SB216763. We
demonstrated that the transcription factor SLUG is present in osteoblasts as well as in their mesenchymal
precursors obtained from Wharton’s Jelly of human umbilical cord and induced to osteoblastic differentiation. We
found that SLUG is positively correlated with RUNX2 expression and deposition of mineralized matrix, and is
regulated by Lef-1 and b-catenin. Consistently, Chromatin Immunoprecipitation (ChIP) assay, used to detect the
direct Lef/Tcf factors that are responsible for the promoter activity of SLUG gene, demonstrated that Lef-1, TCF-1
and TCF4 are recruited to the SLUG gene promoter “in vivo“.
Conclusion: These studies provide, for the first time, the evidence that SLUG expression is correlated with
osteogenic commitment, and is positively regulated by Lef-1 signal in normal human osteoblasts. These findings
will help to further understand the regulation of the human SLUG gene and reveal the biological functions of
SLUG in the context of bone tissue.
Background
Lymphoid Enhancer binding Factor-1 (Lef-1) is a
nuclear high mobility group (HMG) protein that med-
iates gene transcription in response to canonical Wnt/b-
catenin signaling pathway [1-3]. Wnt signaling controls
normal and abnormal development in a variety of tis-
sues including skeleton, and accumulated evidence has
shown that Lef-1 influences osteoblast proliferation,
maturation, function, and regeneration both in vitro and
in vivo [4-7]. Nevertheless, the exact mechanism by
which Lef-1 affects osteoblast differentiation is
unknown. In a search for Lef-1 responsive genes in
human osteoblasts, we focused on the transcriptional
regulation of the SLUG gene for the reasons reported
below.
SLUG, also named SNAIL2, is a member of a super-
family of zinc-finger transcription factors that play a
central role in the patterning of vertebrate embryos
[8-10]. It is implicated in the induction of epithelial
mesenchymal transitions (EM T )a ts p e c i f i cs t a g e so f
normal development and tumor progression, acting as a
transcriptional repressor of genes encoding components
of cell-cell adhesive complexes in the epithelia [11-17].
Several signalling pathways inducing EMT cellular event
and including FGF, WNT, TGF-b,B M P ,E G F ,H I F ,
Notch, PTH, integrins and SCF/c-Kit have been shown
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by Barrallo-Gimeno et al. [18], and as previously
reported [9,10,19].
SLUG and its family members also have important
roles in other processes, including protection of cells
from programmed cell death, regulation of cytoskeletal
elements [18], adipocyte differentiation [20] and migra-
tion of neural crest cells [21,22]. Although the expres-
sion of SLUG has been found in most normal adult
human tissues [23-25], little is known about its potential
functions.
It is important to underline that the vertebrate neural
crest, formed at the border between the neural plate
and the non-neural ectoderm during neurulation, is
able, under SLUG control, to give rise to different cell
types including neurons, glia, facial chondrocytes, osteo-
blasts, and melanocytes [8,26,27]. In addition, craniofa-
cial abnormalities have been observed in association
with cerebral malformations and cutaneous lesions in
some neurocutaneous syndromes, emphasizing an
important inductive role of the neural tube in the devel-
opment of non-neural tissues mediated through neural
crest and differentiating genes such as SLUG and Sox10
[28,29]. Overall, these observations encourage investiga-
tion on SLUG expression and functions in adult cells,
including osteoblasts.
We recently demonstrated, by a knockdown approach,
that SLUG is involved in the differentiation and matura-
tion process of normal human osteoblasts [30]. Never-
theless, so far, no data have been presented on SLUG
regulation in these cells and their precursors. Only one
previous investigation has demonstrated that Wnt sig-
naling regulates SLUG expression, in a tumor model,
such as an osteosarcoma cell line, mediating cancer
invasion [31].
T h ep r e s e n c eo fp u t a t i v ecis elements for Lef-1, in
human SLUG gene promoter has raised the possibility
that Lef-1 may be implicated in the modulation of
SLUG expression as previously demonstrated in other
species such as chick and Xenopus [32,33]. In this study
we demonstrated that SLUG is expressed in both nor-
mal human osteoblasts and their mesenchymal precur-
sors, and that Lef-1 is recruited “in vivo“ to its promoter
acting as a positive transcriptional regulator.
Results
SLUG expression in human osteoblasts and their
mesenchymal precursors
Lef-1 has been shown to play a role in osteoblast differ-
entiation and function. Owing to the relationship
between Lef-1, b-catenin and SLUG recently found in
some epithelial-mesenchymal transition cellular models
[34,35], we hypothesized that Lef-1 and SLUG may also
be correlated in osteoblast lineage cells. To test this idea
SLUG expression was examined during osteoblast differ-
entiation and compared with Lef-1 expression levels.
SLUG mRNA levels were measured in human mesench-
ymal stem cells (hMSCs) obtained from umbilical cord
Wharton’s Jelly and induced towards osteogenesis, as
previously described [36]. RNA was collected after 0, 7,
14, 21, and 28 days in culture and evaluated by quanti-
tative RT-PCR. As shown in Figure 1A, these cells dif-
ferentiate along the osteoblast lineage in osteogenic
medium as confirmed by the positive staining for extra-
cellular calcium deposition. Abundant SLUG mRNA
was detected in the cells at all times tested, and was
induced as the cultures progressed. Lef-1 was less abun-
dant, but significantly increased during the osteogenesis.
RUNX2, a determinant transcription factor for osteo-
blastogenesis [37], was also expressed at all stages, and
was induced as the cultures progressed, confirming that
each time point represented increasingly mature
osteoprogenitors.
In order to confirm that the expression profile that we
found was associated with osteoblast phenotype, SLUG,
Lef-1 and RUNX2 expression levels were measured in
human primary osteoblasts obtained from five bone spe-
cimens (hOBs). All these samples were positive for alka-
line phosphatase (ALP) activity, a well-known osteoblast
differentiation marker, and were able to form minera-
lized nodular structures after 14 days in osteogenic con-
dition (see a representative experiment in the panel of
F i g u r e1 B ) .A ss h o w ni nF i g u r e1 B ,S L U G ,L e f - 1a n d
RUNX2 were detected in all hOB samples analyzed. The
level of SLUG mRNA in hOBs was also compared with
that found in different osteoblast-like cell lines [Addi-
tional file 1].
To further characterize the potential involvement of
SNAIL family members in osteogenesis, the expression
of SNAIL1 and SNAIL3 was examined in the same set
of experiments. SNAIL1 has been recently reported to
act on the osteoblast population regulating bone cells
differentiation and contributing to bone remodeling in
mice [38]. In agreement witht h i sp r e v i o u ss t u d y ,w e
found that SNAIL1 was expressed at early stages of
osteoblast differentiation and then downregulated for
differentiation to proceed (Figure 1A). In hOB samples
SNAIL1 was expressed at substantial levels (Figure 1B).
The expression of SNAIL3 [39] was detectable at very
low levels in the hMSCs induced towards osteogenesis
(Figure 1A), and at low levels in hOBs (Figure 1B).
SLUG expression is positively modulated by Lef-1
hOBs were then transfected with expression vector con-
taining hLef-1 cDNA (K14-myc-hLEF1) as described in
the Methods section. As shown in Figure 2, SLUG
expression significantly increased in Lef-1 overexpres-
sing cells, both at mRNA and protein level, as
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Figure 1 Detection of SLUG expression by quantitative RT-PCR.T h el e v e lo fS L U G ,R U N X 2L e f - 1 ,S N A I L 1a n dS N A I L 3e x p r e s s i o nw a s
examined by quantitative RT-PCR in three hMSC samples cultured up to 28 days in osteogenic medium (A) and in five hOB samples (B). The
cDNA obtained from total RNA was subjected to quantitative TaqMan RT-PCR for SLUG, RUNX2, Lef-1, SNAIL1 and SNAIL3 transcript analysis. The
experiments were carried out in triplicate, the expression levels were normalized on the basis of GAPDH expression and results of the
experiments are reported as relative mRNA expression levels. ΔΔCt method was used to value the gene expression; standard error of the mean
(SEM) was calculated. The commitment to osteoblastic lineage of hMSCs was evaluated by Alizarin Red staining for extracellular calcium
deposition. The authentic osteoblast phenotype was confirmed in hOBs by staining for alkaline phosphatase (ALP) activity and mineralized matrix
deposition (AR, Alizarin Red staining). * = p < 0.05 (respect to day 0).
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analysis (Figure 2B). The significant increase of Lef-1 in
the cells transfected with hLef-1 expression vector was
confirmed by the same Western blot analysis (Figure
2B). As expected, forced expression of Lef-1 increased
Slug expression to higher levels in SaOS-2 osteoblast-
like cells than in hOBs, because of a higher intrinsic
transfection facility of this cell line.
The ability of Lef-1 to activate transcription of SLUG
gene was then tested on the human SLUG promoter
(Figure 3). We chose to focus on an approximately 1 Kb
fragment upstream of the transcription start site in the
SLUG gene since it contains sequences involved in the
regulation of promoter activity mediated by b-catenin
[34]. In addition to the previously identified TCF bind-
ing site at -859/-855 position [34,35], we identified, in
this region, another five potential consensus binding
sites for the Lef/Tcf family by using the programs Tran-
scription Element Search Software TESS for transcrip-
tion factor search and MatInspector 7.4 program (Figure
3A). The sequence was cloned upstream of the Luc
reporter gene in the pGL3basic vector, and the con-
struct, (named 982 bp luc-construct), was assayed after
osteoblast transfections performed with or without Lef-1
expression plasmid. As shown in Figure 3B, transient
transfection with the luciferase reporter 982 bp luc-con-
struct resulted in an increase in luciferase activity rela-
tive to the empty, promoterless pGL3-basic vector,
demonstrating that this DNA fragment contains signifi-
cant promoter activity in hOBs (5-10 fold increase). Co-
transfection with plasmid encoding Lef-1 produced a
significant increase in Luc activity as compared with
cells containing the 982 bp luc-construct reporter plas-
mid. This increase was dramatic in Lef-1 overexpressing
SaOS-2 cells. On the contrary, the same experiments
performed in the non-osseous SLUG-negative MCF7
breast cancer cell line revealed no promoter activity.
As a whole, these data indicate that Lef-1 upregulates
SLUG gene expression in normal human osteoblasts.
Lef-1 is recruited to the SLUG promoter “in vivo”
Next, we investigated whether Lef-1 could, “in vivo“,
physically bind with the human SLUG promoter. Con-
sidering that in addition to Lef-1, among TCF family
members, both TCF-1 and TCF-4 are expressed in
osteoblasts [2], the analysis was addressed to all three
proteins. The binding of transcription factor to the
SLUG promoter was verified by performing in vivo
chromatin immunoprecipitation (ChIP) assays (Figure
3C). To this aim, hOBs were exposed to formaldehyde
to cross-link proteins and DNA, and were sonicated to
fragment the chromatin. Specific antibody against Lef-1,
TCF-1 and TCF-4 were used to immunoprecipitate the
protein-DNA complexes. After immunoprecipitation,
DNA was extracted from the beads and used as a tem-
plate to generate specific PCR products. The presence of
the promoter specific DNA region before immunopreci-
pitation was confirmed by PCR (input). In the SLUG
promoter fragment used for the reporter assay, three
different regions were identified, as depicted in Figure
3A, and analyzed by a set of primers spanning the six
consensus binding sites for the Lef/Tcf family. The
amplified product sizes (bp) were 178 for region 1, 164
for region 2, and 165 for region 3. The results showed
that the promoter region 3, containing the previously
identified TCF binding site at -859/-855 position
[34,35], was significantly immunoprecipitated by Lef-1
and TCF4 antibodies, but that Lef-1 was mostly asso-
ciated with the promoter region 1 and not at all with
the promoter region 2 (Figure 3C). On the contrary, we
found that region 2 was rather occupied by TCF-1 and
TCF-4. Therefore, the observation that the endogenous
SLUG gene expression may be increased by Lef-1 was
further validated by the in vivo occupancy of the Lef/
TCF regulatory sites in the SLUG gene promoter.
Activation of Wnt signaling by GSK-3b inhibitor increases
SLUG promoter activity
It has been demonstrated that b-catenin promotes Lef/
Tcf interaction with target DNA sequence in many cel-
lular contexts. In order to support the role of Lef/Tcf
transcription factors in SLUG expression regulation, we
next investigated whether b-catenin activation was
involved in SLUG expression regulation. We used a
treatment with SB216763 as a model for b-catenin acti-
vation (Figure 4A). This compound binds and specifi-
cally inhibits glycogen synthase kinase GSK-3b. GSK-3b
is a serine/threonine kinase, originally identified as a
kinase that is involved in glucose metabolism, but recent
research has determined that it acts on a wide variety of
substrates, including transcription factors, and is a key
regulator in many signalling pathways [40]. This enzyme
is known to be a key negative regulator of canonical
Wnt/b-catenin and PI3K/Akt signalings [41]; hence, its
inhibition activates Wnt signalling selectively via the b-
catenin/TCF pathway and results in relocation of stabi-
lized b-catenin to the nucleus. As expected, the
SB216763-treated cells transfected with the b-catenin/
Tcf transcription reporter construct -TOPflash reporter
system- showed an increase in TOPflash activity up to
4-fold (Figure 4B). The b-catenin/Tcf transcription
reporter assay was recognised as an important assess-
ment method for evaluation of the Wnt pathway activ-
ity. As TOPflash has three TCF-binding sites, it could
be applied to represent the activation of the Wnt path-
way. In fact, our data showed that SB216763 treatment
positively affected b-catenin expression, as revealed by
Western blot reported in Figure 4C. The dose- and
Lambertini et al. BMC Molecular Biology 2010, 11:13
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Figure 2 Effect of Lef-1 overexpression on SLUG expression in hOBs. The effect of Lef-1 overexpression was examined at mRNA (A) and
protein (B) level. (A) SLUG mRNA was evaluated by quantitative RT-PCR in hOBs and SaOS-2 osteoblast-like cells transfected with 2.5 μg of hLef-
1 (K14-myc-hLEF1) expression plasmid. The cDNA obtained from total RNA was subjected to quantitative TaqMan RT-PCR for SLUG transcript
analysis. The expression levels were normalized on the basis of GAPDH expression and results of the experiments are reported as relative mRNA
expression levels. Results are representative of three independent experiments carried out in triplicate. ΔΔCt method was used to compare gene
expression data; standard error of the mean (SEM) was calculated. * = p < 0.05. (B) SLUG protein levels were examined by Western blot analysis
in hOBs and SaOS-2 osteoblast-like cells transfected with 2.5 μg of hLef-1 expression plasmid. Whole cell lysates were prepared and 25 μgo f
protein run on a 12% SDS-polyacrylamide gel. The proteins were visualized using Supersignal West Femto Substrate (Pierce). The quantitative
presentation of the protein levels were performed by densitometric analysis using Anti-IP(3)K as control. D.U. = densitometric units. This
experiment was repeated three times with similar results. A representative SLUG and Lef-1 Western blot analysis with size markers (KDa) is
reported. * = p < 0.05.
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Page 5 of 12time-response to SB216763 cell treatment was analyzed
in terms of SLUG mRNA levels in osteoblast-like cell
lines [Additional file 2]. The same analysis demonstrated
that the increase in b-catenin mediated by SB216763
was correlated with a significative increase in SLUG and
RUNX2 expression both at protein (Figure 4C) and
mRNA level (data not shown). Therefore, on the whole,
this suggests that the canonical Wnt signaling positively
affects SLUG expression in normal human osteoblasts
via the b-catenin/TCF pathway because, by potentiating
b-catenin, SLUG expression increases.
Discussion
In this paper we have demonstrated that the transcrip-
tion factor SLUG is present in normal human osteo-
blasts and their mesenchymal precursors. Osteoblasts
are the primary cell type responsible for the bone remo-
deling process, and alterations in this pathway can lead
to osteopenic disorders such as osteoporosis. Therefore,
any new marker or mechanism associated with differen-
tiation of these cells represent very relevant information
for the study of bone biology and bone-related diseases
in general.
We have shown that SLUG expression increases dur-
ing osteogenesis, and is positively regulated by Lef-1, an
osteoblastic transcription factor which we found in vivo
recruited by specific cis elements present in the SLUG
promoter. In the SLUG promoter region of approxi-
mately 1 Kb upstream of the transcription start site, we
found at least six potential consensus binding sites for
the Lef/Tcf family, and not just one only at -859/-855
position, as recently reported [34,35]. We found that the
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Figure 3 Lef-1 affects the activity of human SLUG promoter “in vitro“ and binds it “in vivo“.( A )T h eS L U Gp r o m o t e rr e g i o nu n d e r
investigation is reported. The positions of putative Lef/Tcf binding sites are enclosed by rectangles and are compared with those recently
investigated by others. Positions of PCR primers used in ChIP experiments are also reported. (B) The DNA construct containing the human SLUG
promoter region was cloned into upstream of the firefly luciferase (LUC) reporter gene. hOBs and SaOS-2 osteoblast-like cells were transfected
with the pGL3-SLUG Luc reporter vector containing the sequence from +1 to -982 of the human SLUG promoter (pGL3-SLUG 982 bp), in the
absence (-) or presence (+) of 2.5 μg of hLef-1 expression plasmid. The results of reporter gene assays were normalized with protein
concentration and b-gal activity for transfection efficiency and the data are represented as ratios of luciferase units to b-galactosidase units.
MCF7 breast cancer cell line was used as negative control. All experiments were performed in triplicate and the average of the ratio of the
reporter activity + SEM is shown. * = p < 0.05. (C) Recruitment of Lef1/TCF transcription factors to the human SLUG promoter is demonstrated
by “in vivo“ chromatin immunoprecipitation (ChIP) binding assays. Soluble chromatin was prepared from hOBs and immunoprecipitated with the
indicated specific antibodies against Lef-1, TCF-1, and TCF-4. The associations of the transcription factors to bound precipitated DNA were
monitored on the human SLUG promoter regions 1, 2 and 3 by PCR with the primers indicated in the scheme. Input represents a positive
control using the starting material (0.2%) prior to immunoprecipitation. Representative agarose gels are shown.
Lambertini et al. BMC Molecular Biology 2010, 11:13
http://www.biomedcentral.com/1471-2199/11/13
Page 6 of 12sequence regions containing these sites are all involved,
even if at different levels, in the in vivo recruitment of
Lef/Tcf factors, including Lef-1, TCF-1 and TCF-4, in
human osteoblasts. The investigations on the only pre-
viously characterized TCF binding site (-859/-855),
demonstrated its ability to recruit TCF-4 in SW480
human colon cancer [35], but not in Hec251 endome-
trial cancer cell line [34] where, on the contrary, SLUG
expression seems to be under transcriptional control of
b-catenin without the binding of Lef/Tcf factors at this
site. Other studies in different experimental models
provide evidence that Xenopus and mouse SLUG pro-
moters are directly activated by b-catenin/TCF com-
plexes through the binding sequences [32,33], and that
SLUG promoter activity may be inhibited by dominant
negative Tcf [42]. Combined with these reports, our
results may lead to the hypothesis that, directly or indir-
ectly, SLUG and Lef-1 are strictly correlated in many
cellular events, including osteoblast differentiation,
mediated by Wnt/b-catenin signalling. In addition, this
is supported by our recent evidence demonstrating the
requirement of SLUG for osteoblast maturation and the
Figure 4 Treatment of hOBs with the glycogen synthase kinase (GSK-3b) inhibitor, SB216763. (A) A scheme of SB216763 action
mechanism is reported (see the text for details). (B) Effect of SB216763 on the TOPflash reporter system. 24 h after transient transfection with
the TOPflash plasmid, the cells were treated (+) or not (-) with SB216763 (10 μM) for 24 h prior to harvest. Luciferase activity was normalized to
b-galactosidase activity in the same sample. The bars represent mean ± SEM. * = p < 0.05. (C) The levels of b-catenin expression, SLUG and
RUNX2 were examined by Western blot in hOBs treated with SB216763 (10 μM) or with the only vehicle (-). The quantitative presentation of the
protein levels was performed by densitometric analysis using Anti-IP(3)K as control. D.U. = densitometric units. A representative Western blot
analysis with size markers (KDa) is reported. * = p < 0.05.
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Page 7 of 12decrease in Wnt/b-catenin signalling after SLUG knock-
down [30]. This suggests a possible role of SLUG as
effector of Wnt/b-catenin signalling.
Our findings confirm a relationship between SLUG
and Wnt signalling showing that the increase in b-cate-
nin levels, obtained by the suppression of GSK-3b activ-
ity with SB216763 inhibitor, induces a significative
SLUG gene expression increase. b-catenin is known to
associate with the Lef/Tcf transcription factor family
and promote the expression of several genes through
the recruitment of other factors to form a transcription-
ally active complex [43,44]. Lef-1 is reported to have an
important role in osteoblast maturation for its ability in
the regulation of expression of genes involved in the sti-
mulation of bone formation, such as RUNX2 and
Col11a1 [45,46]. In addition, an age- and gender- depen-
dent role for Lef-1 in regulating bone formation in vivo
has recently been described [7]. The discovery that
SLUG expression is upregulated during osteogenesis, is
positively correlated with the expression of RUNX2 and
Lef-1, and is under the control of Lef-1, corroborates
the role of Lef/Tcf transcription factors in osteoblasts
and highlights mechanisms by which Lef-1 may affect
maturation and differentiation of these cells. Our results
further support the hypothesis that SLUG may have a
distinct role in normal human osteoblasts, and may be
positively regulated by activity of canonical Wnt/b-cate-
nin signalling pathway. Therefore, as far as bone tissue
is concerned, SLUG should not be considered exclu-
sively as a marker of malignancy and an attractive target
for therapeutic modulation of bone metastasis and
osteosarcoma invasiveness, as indirectly suggested by
Guo et al. [31].
Considering the widespread expression of SLUG in all
osteoblast samples analyzed, we cannot exclude that
SLUG, which encodes an evolutionarily conserved antia-
poptotic transcription factor, may confer a survival
advantage in osteoblasts, as demonstrated for leukemic
B cell progenitors [47].
In conclusion, although further studies are required to
elucidate whether the two Lef-1 isoforms recently iden-
tified [6] may have distinguishable activities in determin-
ing the proper levels of SLUG expression, our study
clearly shows that b-catenin/Lef-1 signalling is involved
in the regulation of this gene in normal human osteo-
blasts. In addition, other factors may contribute to the
SLUG gene regulation. At present, the relationship
between other cis-regulatory elements in the SLUG pro-
moter and osteoblast-inducing signals is completely
unknown. The most likely candidates for this function
are SLUG and RUNX2, which could associate with the
E boxes and RUNX binding sites present in the promo-
ter. Therefore, further work will be necessary to evaluate
a potential transcription autoregulation and to elucidate
the association between SLUG and RUNX2 expression.
Our hypothesis is that SLUG might represent an inter-
esting molecule for normal skeletogenesis acting inside
the recently proposed [48] large signalosome in which
inputs from Wnt/b-catenin/Lef-1 signalling, steroid
receptors, BMPs, and kinases converge to induce differ-
entiation of osteoblast precursors. With this in mind, we
also speculate that study of the association between
SLUG and some organizers of osteoblastic phenotype
may improve the characterization of the human osteo-
blast differentiation stages. In particular, this may be
relevant in approaches addressed to the discovery of
new molecular targets to use in bone repair and regen-
erative medicine.
Conclusions
In this study we showed that transcription factor SLUG
is expressed in both normal human osteoblasts and
their mesenchymal precursors, and that Lef-1, a media-
tor of the Wnt/b-catenin signalling pathway, is recruited
“in vivo“ to its promoter acting as a positive transcrip-
tional regulator. The relationship between SLUG and
Wnt signalling has been confirmed demonstrating that
increase in b-catenin levels induced a significative SLUG
gene expression increase.
In conclusion, our findings reveal the biological func-
tions of SLUG in the context of bone tissue showing
that it is positively correlated with the osteogenesis, and
highlights mechanisms by which Lef-1 may affect
maturation and differentiation of osteoblasts.
Methods
Construction of reporter plasmid
Promoter region (+1 to -982 bp) of the human SLUG
promoter was amplified by PCR from human genomic
DNA using SLUG F genomic primer as sense primer
and SLUG R genomic primer as antisense primer (Table
1). The PCR product was subcloned upstream of a fire-
fly luciferase (LUC) gene in the promoter-less pGL3-
Basic vector (Promega, Madison, WI) using MluI and
BglII restriction sites, and the presence of the insert was
confirmed by restriction digestion.
Cell culture, plasmids and transient transfection
Human primary osteoblasts were obtained from bone
samples collected during nasal septum surgery, and were
cultured as previously described [49]. Recruitment of
subjects donating osteoblasts was in accordance with
approved procedures, and informed consent was
obtained from each patient. Briefly, the bone was cut into
small pieces which were rinsed and then cultured in
Eagle’s MEM (Sigma Aldrich, St. Louis, MO, USA) sup-
plemented with 20% fetal bovine serum (FBS) (CELBIO
EuroClone, Milan, Italy), 2 mM glutamine, 100 units/ml
Lambertini et al. BMC Molecular Biology 2010, 11:13
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Page 8 of 12penicillin, 100 μg/ml streptomycin, and 50 μg/ml ascor-
bate at 37°C in a humidified atmosphere of 5% CO2.
After about 5-7 days, outgrowth of bone cells from the
bone chips commenced, and confluency in 9 cm
2 dishes
was usually reached after 4-6 weeks. For the studies here
presented, only first passage cells were used.
Mesenchymal stem cells were obtained from Whar-
ton’s Jelly of human umbilical cord after the mothers’
consent and approval of the “Ethical committee of Uni-
versity of Ferrara and S.Anna Hospital “, and character-
ized as previously described [36].
The expression vector for full-length Lef-1 (K14-myc-
hLEF1) was a gift from Elaine Fuchs and Rebecca C.
Lancefield (Howard Hughes Medical Institute, The
Rockfeller University, Lab. of Mammalian Cell Biology
& Development, New York U.S.A.). The TCF reporter
plasmid TOP FLASH was kindly provided by Rolf Kem-
ler (Max Planck Institute, Heidelberg, Germany).
For transient transfection assays, 50000 cells/ml were
seeded in 24 or 6 multiwell plates. After 24 h, cells were
transfected using Lipofectamine reagent (Invitrogen,
Carlsbad, CA) and 0.5 μg of reporter construct where
not specified.
SB216763 was purchased from Sigma (Sigma Aldrich,
St. Louis, MO, USA), and dissolved in DMSO.
Analysis of the osteoblast phenotype
For alkaline phophatase staining, prefixed mono-layered
cells were incubated at room temperature in a solution
containing naphthol AS-BI phosphate and freshly pre-
pared fast blue BB salt buffered at pH 9.5 with 2-amino-
2-methyl-1,3-propanediol (Alkaline Phosphatase Leuko-
cyte kit, Sigma). The presence of sites of ALP activity
appeared as blue cytoplasmatic staining.
The extent of mineralized matrix in the plates was
determined by Alizarin Red S staining (Sigma) in the
cells cultured for up to 35 days in osteogenic medium
consisting in DMEM, high-glucose, supplemented with
10% FBS, 10 mM b-glycerophosphate, 0.1 mM dexa-
methasone and 50 mM ascorbate. In the committed
cells, the osteogenic medium was changed every three
days. The cells were then fixed in 70% ethanol for 1 h at
room temperature, washed with PBS, stained with 40
mM AR-S (pH 4.2) for 10 min. at room temperature,
washed five times with deionized water and incubated in
PBS for 15 min. to eliminate non-specific staining. The
stained matrix was observed at different magnifications
using a Leitz microscope.
Luciferase reporter gene assays
For experiments assessing activation of the SLUG pro-
moter, 1 μg of reporter plasmid was cotransfected with
2.5 μg of expression vectors for Lef1 (K14-myc-hLEF1)
and 0.25 μgo fp C M V - S p o r t - bgal (Invitrogen). The cells
were lysed 48 h after transfection using the reporter
lysis buffer (Promega, Madison, WI). Luciferase and b-
galactosidase activities were determined with luciferase
and Beta-Glo assay systems respectively (Promega,
Madison, WI). Their activities were normalized with
respect to total protein amount.
Real-time RT-PCR analysis
For mRNA analysis total cellular RNA was extracted
using Total RNA Isolation System (Promega) and cDNA
synthesis was performed for 1 h at 42°C using 1 μgo f
total RNA as a template and 100 U of reverse transcrip-
tase ImProm-II (Promega) as previously described [49].
The level of mRNA expression was analyzed by quanti-
tative real-time PCR using the ABI Prism 7700 system
(Applied Biosystems) and the following TaqMan MGB
probes: 5’ FAM-ATGATGAAAGGTGGGATAC-
GAAAAG-TAMRA 3’ for SLUG, 5’ FAM-GAACCCA-
GAAGGCACAGACAGAAG-TAMRA 3’ for RUNX2, 5’
FAM-TCTAATCCAGAGTTTACCTTCCAGC-TAMRA
3’ for SNAIL1, 5’FAM-GAGACGCAGAGAGAAAT-
CAATGGTG-TAMRA 3’ for SNAIL3, and 5’ FAM-
CATGTCCAGGTTTTCCCATCATATG-TAMRA 3’ for
Lef-1; GAPDH mRNA was used as an endogenous con-
trol (Applied Biosystems Inc, Foster City, CA, USA) and
quantification was performed using a TaqMan assay.
The mRNA levels of target genes were corrected for
GAPDH mRNA levels. All PCR reactions were per-
formed in triplicate for each sample and were repeated
three times. All experimental data were expressed as the
mean ± SEM.
Western Blot analysis
For Western Blot analysis, the cells were washed twice
with ice-cold PBS and cell lysates were prepared as pre-
viously reported [50]. 25 μg of each sample was then
Table 1 Primers used in this study
Oligo name Primer sequences 5’-3’
Primers for reporter construct
Slug F TGTCAAAAGTGTGAGAGAAT
Slug R CTTGCCAGCGGGTCTGGC
Primers for ChIP
Region 1 F GAGGTTACCTCTCTTGAAAATACT
Region 1 R GGAAGAAAGATCCAATCACA
Region 2 F CCAGGCCAGATCCCAGGAGAGC
Region 2 R GCCTCTGGTGTTAATGAGAGCCTA
Region 3 F TGCCCCCCTTCTCTGCCAGAGTT
Region 3 R TTCCGCGAAGCCAGGGGCAGCG
The sequence and the name of the forward (F) and reverse (R) primers for the
construction of reporter plasmid and for Chromatin immunoprecipitation
(ChIP) are reported.
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proteins were then transferred onto an Immobilon-P
PVDF membrane (Millipore Corporation, 900 Middlesex
Tpk Billerica, USA). After blocking with PBS-0.05%
Tween 20 and 5% dried milk, the membrane was probed
with the following antibodies: SLUG (L40C6) from Cells
Signaling Technology Inc. (Danvers, CA, USA), RUNX2
(sc-10758) from Santa Cruz Biotechnology (Santa Cruz,
CA), Lef-1 (L7901) from Sigma Aldrich (St Luis, MO,
USA), IP3K (06-195) and Active-b-catenin from Upstate
Biotechnology, Inc. (Lake Placid, NY). After washing
with PBS-Tween, the membranes were incubated with
peroxidase-conjugated anti-rabbit antibody (1:50000) or
anti-mouse (1:2000) (Dako, 2600 Glostrup, Denmark) in
5% non-fat milk. Immunocomplexes were detected
using Supersignal West Femto Substrate (Pierce). Anti-
IP(3)K was used to confirm equal protein loading.
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was carried out as previously described
[49] using the standard protocol supplied by Upstate
Biotechnology (Lake Placid, NY) with their ChIP assay
reagents.
The cells were cross-linked with 1% formaldehyde for
10 min at 37°C, washed in ice-cold PBS and resuspended
in SDS lysis buffer for 10’ on ice. Samples were sonicated,
diluited 10-fold in diluition buffer supplemented with
protease inhibitors and precleared with 80 μlo fD N A -
coated protein A-agarose; the supernatant was used
directly for immunoprecipitation with 5 μg of anti- Lef-1
(sc-8591), TCF-1 (sc-13025) and TCF-4 (sc-13027)
(Santa Cruz Biotec, Ca, USA) overnight at 4°C. Immuno-
complexes were mixed with 80 μl of DNA-coated protein
A-agarose followed by incubation for 1 h at 4°C. Beads
were collected and sequentially washed 5 times with 1 ml
each of the following buffers: low salt wash buffer (0.1%
SDS,1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl
pH 8.1, 150 mM NaCl), high salt wash buffer (0.1%
SDS,1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl
pH-8.1, 500 mM NaCl), LiCl wash buffer (0.25 mM LiCl,
1% IGEPAL-CA630, 1% deoxycholic acid, 1 mM EDTA,
10 mM Tris-pH 8.1) and TE buffer. The immunocom-
plexes were eluted two times by adding a 250 μla l i q u o t
of a freshly prepared solution of 1% SDS, 0.1 M NaHCO3
and the cross-linking reactions were reversed by incuba-
tion at 65°C for 4 h. Further, the samples were digested
with proteinase K (10 mg/ml) at 42°C for 1 h, DNA was
recovered by phenol/chloroform extractions, ethanol pre-
cipitated using 1 μl of 20 mg/ml glycogen as the carrier,
and resuspended in sterile water. For PCR analysis, ali-
quots of chromatin before immunoprecipitation were
saved (Input). PCR was performed to analyze the pre-
sence of DNA precipitated by specific antibodies by using
the primers reported in Table 1.
Each PCR reaction was performed with 10 μlo ft h e
bound DNA fraction or 2 μl of the input. The PCR was
performed as follows: preincubation at 95°C for 5’,3 0
cycles of 1’ denaturation at 95°C, 1’ annealing at 62°C
and 1 min at 72°C, with one final incubation at 72°C for
5’. No-antibody control was included in each
experiment.
Statistical analysis
Data are presented as the mean ± SEM from at least
three independent experiments. Statistical analysis was
performed by one-way analysis of variance and the Stu-
dent’s t-test. A P value < 0.05 was considered statisti-
cally significant.
Additional file 1: Detection of SLUG expression by quantitative RT-
PCR in osteoblastic-like cell lines and hOB samples. The level of
SLUG was examined by quantitative RT-PCR in U2OS, SaOS-2, Hobit,
CAL72 osteoblastic-like cell lines and in eight hOB samples. MCF7 breast
cancer cell line was used as negative control. The cDNA obtained from
total RNA was subjected to quantitative TaqMan RT-PCR for SLUG
transcript analysis. The experiments were carried out in triplicate, the
expression levels were normalized on the basis of GAPDH expression and
results of the experiments are reported as relative mRNA expression
levels. ΔΔCt method was used to value the gene expression; standard
error of the mean (SEM) was calculated.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-
13-S1.PPT]
Additional file 2: Treatment of osteoblastic-like cell lines with the
glycogen synthase kinase (GSK-3b) inhibitor, SB216763. The levels of
SLUG expression was examined by quantitative TaqMan RT-PCR in U2OS,
SaOS-2, Hobit, CAL72 osteoblastic-like cell lines treated with SB216763
(10, 25 and 50 μM) or with the only vehicle (-), up to 3 days.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-
13-S2.PPT]
Abbreviations
Lef-1: Lymphoid Enhancer binding Factor-1; hOBs: human osteoblasts;
hMSCs: human mesenchymal stem cells; FBS: fetal bovine serum; ChIP:
Chromatin Immunoprecipitation; HMG: high mobility group; RUNX2: Runt-
related transcription factor 2; ALP: alkaline phosphatase.
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